LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotechnology consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is an Investor Relations consultancy that provides equity research to clients in Healthcare LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in Pharmaceuticals. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Healthcare Investor consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Pharmaceutical Investor consultancy that provides equity research to clients in Medical Devices.

Web developed by Bolinger web design

Our Distribution


LIFESCI ADVISORS PUBLISHES LOMITAPIDE AND MIPOMERSEN PHYSICIAN SURVEY RESULTS


« Back to News


Survey Shows Strong Preference for Lomitapide Over Mipomersen

Available for Download at http://lifesciadvisors.com/marketresearch/

NEW YORK, NY – July 2, 2012 – LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has published an independent survey of 39 practicing lipidologists who answered on their expected use of Aegerion Pharmaceuticals’ lomitapide and Isis Pharmaceuticals’ mipomersen in patients with Homozygous Familial Hypercholesterolemia (HoFH) or “uncontrollably” high LDL levels, should these two new drugs get approved by the FDA.

 “Based on the results of our proprietary survey of lipidologists, we believe there is much stronger interest in the use of lomitapide over mipomersen for the treatment of patients with extremely high and uncontrollable cholesterol levels,” said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors.  “The 39 survey responders intend to prescribe lomitapide to a total of 254 patients and mipomersen to a total of 152 patients. “Regarding efficacy, 44% of the responders view lomitapide as very efficacious compared to 13% for mipomersen. Regarding safety, 62% of the responders view lomitapide as moderately safe compared to 43% for mipomersen.“

Lomitapide, a microsomal triglyceride protein inhibitor, is a once-daily pill being developed by Aegerion Pharmaceuticals for the HoFH indication. It has a PDUFA data of December 29, 2012. Aegerion holds exclusive worldwide rights to lomitapide. Mipomersen is an apolipoprotein-B (apo-B) synthesis inhibitor co-developed by Isis and Genzyme, which has a January 29, 2013 PDUFA date for the HoFH indication.

« Back to News

Contact Us   |   About Us   |   Privacy Policy   |   Disclaimer  |   Careers

©2014 LifeSci Advisors, LLC. All Rights Reserved.

email


Web developed by Bolinger web design